The firms launched OptraScan's Global TelePath Network in the UAE, India, and South Africa under the partnership, named Neuberg Digipath, Powered by OptraScan.
The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
Opko will use the proceeds to fund R&D to further develop its diagnostics and pharmacy portfolio, and for working capital including debt repayment.
In fiscal Q2, the firm's Diagnostics and Genomics revenues were $39.3 million, up 6 percent year over year from $37.1 million.
Excluding a loss of business to LabCorp, total revenue increased 22 percent year over year in the fourth quarter, Luminex said.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
The Toronto-based partners aim to create a rapid, multiplex test and companion point-of-care device for identifying lung transplant candidates.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
The FDA said that Terrific Care/Medex Supply distributed certain Roche Diagnostics test strip lots in the US even though domestic sales had been stopped due to safety concerns.